Company intelligence / Profile preview
InxMed
Nanjing, Jiangsu, Chinaen.inxmed.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Positive Phase Ib/II results for ifebemtinib in combination with garsorasib in NSCLC with KRAS G12C mutation. Ifebemtinib has been granted Breakthrough Therapy Designation from China NMPA and Fast-Track designation from US FDA. Over 600 patients have been treated with ifebemtinib with favorable safety and tolerability profile.
- Therapeutic areas
- Oncology
- Modalities
- Small moleculesantibodiesADC (Antibody-Drug Conjugates)
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Beyond the preview
Go deeper on InxMed.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on InxMed.